LiDCO Group has received approval in China for its LiDCOrapidhaemodynamic monitor.
This means that it can be relaunched later this year. The approval was required because of the need to register a key component of the monitor and this held back sales in the past two years. China is the second largest market in the world.
Annual sales could exceed £500,000. There is little in the current forecasts for revenues from China. The group loss is expected to decline from £2m to £1.1m this year.
© 2019 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Omega Diagnostics will lose money this year, but it is on course to become profitable in 2020-21 as sales of the VISITECT CD4 test.
House broker Shore Capital has slashed its pre-tax profit forecast for engineer Tricorn Group by two-thirds to £420,000.
Evgen Pharma has entered into an agreement with The University of Dundee for the use of SFX-01 in a clinical trial in non-alcoholic steatohepatitis and liver fibrosis, where there is no existing treatment.